A Phase I Trial for Refractory or Relapsed Neuroblastoma With DFMO Alone and in Combination With Etoposide.

Trial Profile

A Phase I Trial for Refractory or Relapsed Neuroblastoma With DFMO Alone and in Combination With Etoposide.

Completed
Phase of Trial: Phase I

Latest Information Update: 29 Oct 2016

At a glance

  • Drugs Eflornithine (Primary) ; Etoposide
  • Indications Neuroblastoma
  • Focus Adverse reactions; Biomarker
  • Most Recent Events

    • 10 May 2016 Status changed from active, no longer recruiting to completed.
    • 02 Jan 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 16 Apr 2012 Planned End Date changed from 1 Jun 2012 to 1 Jun 2016 a reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top